@joshua/drug-interactions-and-organ-dosing
Drug interactions and renal/hepatic dosing
Author-made · not reviewedClinical pharmacyCC BY 4.0
Written by the BenchClub team with AI help. Answers follow public guidelines and textbooks; not yet reviewed by a practising physician.
v130 questionsUpdated Nov 18, 2026
- DDI-001Multiple choiceClinical pharmacyAdvanced
A 78-year-old woman weighing 52 kg with nonvalvular atrial fibrillation (CHA2DS2-VASc 4) is starting rivaroxaban. Serum creatinine 1.2 mg/dL, normal liver function, no combined P-gp and strong CYP3A4 inhibitors. Estimate creatinine clearance with Cockcroft-Gault (actual body weight) and choose the rivaroxaban dose:
- ACrCl about 37 mL/min; rivaroxaban 20 mg once daily
- BCrCl about 32 mL/min; rivaroxaban 10 mg once daily
- CCrCl about 32 mL/min; rivaroxaban 15 mg twice daily
- DCrCl about 32 mL/min; rivaroxaban 15 mg once daily with the evening meal
- ECrCl about 27 mL/min; rivaroxaban is contraindicated
Show answer
Answer D
Source Xarelto (rivaroxaban) US prescribing information (FDA); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
- DDI-002Multiple choiceClinical pharmacyIntermediate
An 82-year-old woman weighing 58 kg has nonvalvular atrial fibrillation. Serum creatinine 1.1 mg/dL; no interacting drugs. The correct apixaban dose is:
- A5 mg twice daily
- B2.5 mg twice daily
- C5 mg once daily
- D2.5 mg once daily
- E10 mg twice daily for 7 days, then 5 mg twice daily
Show answer
Answer B
Source Eliquis (apixaban) US prescribing information (FDA); 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
- DDI-003Multiple choiceClinical pharmacyBasic
A 68-year-old man with type 2 diabetes takes metformin 1000 mg twice daily; HbA1c 7.2%. Two eGFR values over the past 3 months were 39 and 37 mL/min/1.73 m²; urine albumin-to-creatinine ratio 120 mg/g. No acute illness. Regarding metformin, the most appropriate action is:
- AReduce to a maximum of 1000 mg/day and recheck eGFR every 3-6 months
- BContinue 2000 mg/day; no change is needed until eGFR falls below 30
- CStop it now and switch to glyburide
- DStop it now and switch to insulin
- EReduce to 500 mg/day and hold it for 48 hours before every clinic visit
Show answer
Answer A
Source KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease; Glucophage (metformin) US prescribing information (FDA)
- DDI-004Multiple choiceClinical pharmacyBasic
A 60-year-old man takes simvastatin 40 mg nightly with LDL-C at goal; liver and renal function are normal. He is starting itraconazole 200 mg twice daily for chronic pulmonary aspergillosis, planned for at least 6 months. What is the most appropriate lipid-lowering management?
- AReduce simvastatin to 20 mg and monitor creatine kinase
- BSwitch to atorvastatin 40 mg
- CContinue the same dose and add coenzyme Q10 to prevent myopathy
- DContinue the same dose and add fenofibrate
- EStop simvastatin and switch to rosuvastatin or pravastatin
Show answer
Answer E
Source Zocor (simvastatin) US prescribing information (FDA); Sporanox (itraconazole) US prescribing information (FDA); Wiggins et al., AHA Scientific Statement on Statin Drug Interactions, Circulation 2016
- DDI-005Multiple choiceClinical pharmacyBasic
A 71-year-old man with a mechanical mitral valve replacement and atrial fibrillation takes warfarin 5 mg daily with a stable INR of 2.5-3.0. Because of recurrent ventricular tachycardia, he starts an oral amiodarone load today. Regarding warfarin, the most appropriate action is:
- AKeep the same dose and recheck INR in 3 months
- BHold warfarin for 1 week and bridge with aspirin
- CIncrease warfarin by 25% because amiodarone induces its metabolism
- DPre-emptively reduce the warfarin dose by about one-third to one-half, then check INR once or twice weekly until stable
- EKeep the same dose and adjust only if bleeding occurs
Show answer
Answer D
Source Amiodarone tablets US prescribing information (FDA); Warfarin sodium tablets US prescribing information (FDA)
- DDI-006Multiple choiceClinical pharmacyBasic
A 66-year-old man is on dual antiplatelet therapy (aspirin plus clopidogrel) after PCI for acute coronary syndrome. He has a history of peptic ulcer bleeding and needs a proton pump inhibitor. According to the clopidogrel prescribing information, which is most appropriate?
- APantoprazole
- BOmeprazole
- CEsomeprazole
- DCimetidine
- ENo acid suppression
Show answer
Answer A
Source Plavix (clopidogrel) US prescribing information (FDA); 2010 ACCF/ACG/AHA Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines; 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
- DDI-007Multiple choiceClinical pharmacyIntermediate
A 52-year-old woman takes sertraline 100 mg daily for depression. She is started on IV linezolid 600 mg every 12 hours for a vancomycin-resistant Enterococcus (VRE) intra-abdominal infection. On day 2 she becomes agitated and diaphoretic with diarrhea; T 102.0°F (38.9°C), HR 124/min, mydriasis, lower-extremity hyperreflexia with inducible ankle clonus, and no lead-pipe rigidity. The most likely diagnosis and management are:
- ASerotonin syndrome; stop linezolid and sertraline (switch to another VRE-active agent), give benzodiazepines and supportive care, and cyproheptadine if needed
- BNeuroleptic malignant syndrome; give bromocriptine and dantrolene
- CWorsening intra-abdominal sepsis; escalate to meropenem plus vancomycin
- DSerotonin syndrome; continue linezolid, halve sertraline and add haloperidol for sedation
- ELinezolid-induced lactic acidosis; give sodium bicarbonate and continue linezolid
Show answer
Answer A
Source Zyvox (linezolid) US prescribing information (FDA); Boyer & Shannon, The Serotonin Syndrome, NEJM 2005; FDA Drug Safety Communication on linezolid and serotonergic psychiatric drugs, 2011
- DDI-008Multiple choiceClinical pharmacyAdvanced
A 45-year-old man is 1 year after kidney transplantation on tacrolimus 3 mg every 12 hours, trough 7 ng/mL, with stable renal function. He is diagnosed with invasive pulmonary aspergillosis and voriconazole is to be started. Per the voriconazole prescribing information, how should tacrolimus be managed?
- AKeep the tacrolimus dose and recheck the trough in 1 week
- BReduce tacrolimus to one-half and recheck the trough in 2 weeks
- CWhen voriconazole starts, reduce tacrolimus to one-third of the original dose (1 mg every 12 hours) and monitor troughs closely
- DStop tacrolimus and resume it after voriconazole is finished
- ESwitch to sirolimus, which is safer with voriconazole
Show answer
Answer C
Source Vfend (voriconazole) US prescribing information (FDA); Prograf (tacrolimus) US prescribing information (FDA)
- DDI-009Multiple choiceClinical pharmacyIntermediate
A 58-year-old man with autoimmune hepatitis in remission takes azathioprine 100 mg daily with stable blood counts. He has recurrent gout flares and normal renal function, and urate-lowering therapy is planned. Which statement about urate-lowering therapy is correct?
- AAllopurinol does not interact with azathioprine; start allopurinol 100 mg daily as usual
- BIf allopurinol is used, reduce azathioprine to one-third to one-quarter of the dose (about 25-33 mg daily) and monitor CBCs closely
- CUse febuxostat instead to avoid the interaction with azathioprine
- DIf allopurinol is used, increase azathioprine to 150 mg daily to offset enzyme induction
- EAzathioprine must be stopped with any urate-lowering drug
Show answer
Answer B
Source Imuran (azathioprine) US prescribing information (FDA); Zyloprim (allopurinol) US prescribing information (FDA); Uloric (febuxostat) US prescribing information (FDA)
- DDI-010Multiple choiceClinical pharmacyBasic
A 76-year-old man with HFrEF takes lisinopril 10 mg daily and spironolactone 25 mg daily. eGFR 40 mL/min/1.73 m² (Cockcroft-Gault CrCl about 45 mL/min), potassium 4.9 mEq/L. He now has acute cystitis. He has no fever, flank pain or features of prostatitis. Which antibiotic should most be avoided?
- ANitrofurantoin monohydrate/macrocrystals 100 mg PO twice daily for 5 days
- BFosfomycin 3 g PO as a single dose
- CCephalexin 500 mg PO twice daily for 5-7 days
- DAmoxicillin-clavulanate 500/125 mg PO twice daily for 5-7 days
- ETrimethoprim-sulfamethoxazole 160/800 mg PO twice daily for 3 days
Show answer
Answer E
Source Bactrim (sulfamethoxazole-trimethoprim) US prescribing information (FDA); American Geriatrics Society 2023 Updated Beers Criteria
- DDI-011Multiple choiceClinical pharmacyAdvanced
A 55-year-old 80-kg man has MRSA bacteremia with stable renal function (CrCl about 90 mL/min). On vancomycin 1 g every 12 hours at steady state, Bayesian software estimates AUC24 at 300 mg·h/L (MIC 1 µg/mL). The target AUC24 is 400-600 mg·h/L. Keeping q12h dosing and assuming linear pharmacokinetics, which regimen brings AUC24 into the target range?
- A0.75 g every 12 hours
- B1.25 g every 12 hours
- C1.5 g every 12 hours
- D2.25 g every 12 hours
- E2.5 g every 12 hours
Show answer
Answer C
Source 2020 ASHP/IDSA/PIDS/SIDP Consensus Guideline on Therapeutic Monitoring of Vancomycin for Serious MRSA Infections
- DDI-012Multiple choiceClinical pharmacyAdvanced
A 60-year-old woman with alcohol-related cirrhosis needs caspofungin for Candida glabrata candidemia. Total bilirubin 2.5 mg/dL, serum albumin 3.0 g/dL, INR 1.5, mild ascites, no hepatic encephalopathy. Choose the caspofungin dose based on the Child-Pugh class:
- AChild-Pugh A (6 points); 70 mg loading dose, then 50 mg daily
- BChild-Pugh B (8 points); 70 mg loading dose, then 50 mg daily
- CChild-Pugh C (10 points); caspofungin is contraindicated
- DChild-Pugh B (8 points); 70 mg loading dose, then 35 mg daily
- EChild-Pugh B (8 points); no loading dose, 35 mg daily
Show answer
Answer D
Source Cancidas (caspofungin) US prescribing information (FDA)
- DDI-013Multiple choiceClinical pharmacyIntermediate
An 80-year-old 60-kg man has a left lower-extremity DVT and enoxaparin treatment is planned. Serum creatinine 2.2 mg/dL; no active bleeding. After estimating creatinine clearance with Cockcroft-Gault (actual body weight), the enoxaparin treatment dose is:
- A60 mg SC every 24 hours
- B60 mg SC every 12 hours
- C40 mg SC every 24 hours
- D30 mg SC every 24 hours
- EEnoxaparin is contraindicated
Show answer
Answer A
Source Lovenox (enoxaparin) US prescribing information (FDA), dosing for CrCl <30 mL/min
- DDI-014Multiple choiceClinical pharmacyIntermediate
A 78-year-old 55-kg woman with serum creatinine 2.0 mg/dL is receiving cefepime 2 g every 8 hours (not renally adjusted) for hospital-acquired pneumonia. On day 4 she is afebrile with a falling WBC but develops confusion and multifocal myoclonus. EEG shows nonconvulsive status epilepticus; head CT shows no new lesion; glucose and sodium are normal. The most likely cause and management are:
- ASepsis-associated encephalopathy; escalate to meropenem plus vancomycin
- BWernicke encephalopathy; give IV thiamine and continue the same antibiotics
- CCefepime neurotoxicity; stop cefepime (or switch to another agent), treat seizures, and consider hemodialysis in severe cases
- DNew ischemic stroke; start aspirin
- ECefepime neurotoxicity; keep the same dose and add flumazenil
Show answer
Answer C
Source Maxipime (cefepime) US prescribing information (FDA), renal dosing and neurotoxicity warning; FDA Drug Safety Communication on cefepime and nonconvulsive status epilepticus, 2012
- DDI-015Multiple choiceClinical pharmacyIntermediate
A 45-year-old man with epilepsy takes valproate 1000 mg twice daily; a recent level was 75 µg/mL and he has been seizure-free. He starts meropenem for an ESBL-producing Klebsiella pneumoniae bloodstream infection (resistant to third-generation cephalosporins, piperacillin-tazobactam and fluoroquinolones; susceptible to carbapenems and amikacin). On day 3 he has a generalized tonic-clonic seizure; the valproate level is 12 µg/mL. The most appropriate management is:
- AIncrease valproate to 1500 mg twice daily with an IV load until the level is therapeutic
- BContinue the same regimen and recheck the valproate level in 1 week
- CSwitch meropenem to imipenem-cilastatin
- DStop meropenem and switch to piperacillin-tazobactam
- EContinue meropenem and valproate; add levetiracetam and recheck valproate after the carbapenem ends
Show answer
Answer E
Source Depakote/valproate US prescribing information (FDA); Merrem (meropenem) US prescribing information (FDA); IDSA 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections (AMR Guidance 4.0)
- DDI-016Multiple choiceClinical pharmacyAdvanced
A 65-year-old 60-kg woman with ovarian cancer is to receive carboplatin AUC 5 with paclitaxel. Serum creatinine 0.9 mg/dL. Using the Cockcroft-Gault creatinine clearance (actual body weight) as the GFR in the Calvert formula, the carboplatin dose is closest to:
- AAbout 295 mg
- BAbout 340 mg
- CAbout 420 mg
- DAbout 470 mg
- EAbout 750 mg
Show answer
Answer C
Source Carboplatin injection US prescribing information (FDA); Calvert et al., J Clin Oncol 1989
- DDI-017Multiple choiceClinical pharmacyIntermediate
A 70-year-old man with gout and CKD stage 3b (CrCl 40 mL/min) takes colchicine 0.6 mg daily for flare prophylaxis. He now has confirmed Helicobacter pylori infection and eradication is planned; susceptibility testing is not available. The most appropriate choice is:
- AAvoid clarithromycin; use bismuth quadruple therapy (PPI, bismuth subsalicylate, tetracycline, metronidazole) for 14 days and continue colchicine
- BPPI + amoxicillin + clarithromycin triple therapy, with colchicine reduced to 0.3 mg daily
- CPPI + amoxicillin + clarithromycin triple therapy, monitoring creatine kinase only
- DSubstitute erythromycin for clarithromycin and keep colchicine unchanged
- EPPI + amoxicillin + clarithromycin triple therapy, increasing colchicine to 0.6 mg twice daily to prevent flares
Show answer
Answer A
Source Colcrys (colchicine) US prescribing information (FDA), contraindication with P-gp or strong CYP3A4 inhibitors in renal or hepatic impairment; ACG 2024 Clinical Guideline: Treatment of Helicobacter pylori Infection (Chey et al.)
- DDI-018Multiple choiceClinical pharmacyAdvanced
A 45-year-old man, height 5 ft 9 in (69 in), weight 120 kg (265 lb), with normal serum creatinine (CrCl >100 mL/min) has a gram-negative bloodstream infection. Extended-interval gentamicin 7 mg/kg once daily is planned. Using the Devine formula for ideal body weight and adjusted body weight (IBW + 0.4 × excess), the first dose is closest to:
- AAbout 360 mg
- BAbout 495 mg
- CAbout 840 mg
- DAbout 630 mg
- EAbout 1050 mg
Show answer
Answer D
Source Nicolau et al., Antimicrob Agents Chemother 1995 (Hartford extended-interval aminoglycoside program); The Sanford Guide to Antimicrobial Therapy (aminoglycoside dosing weight in obesity)
- DDI-019Multiple choiceClinical pharmacyIntermediate
A 70-year-old 70-kg man has MRSA bacteremia and is being switched to daptomycin 8 mg/kg (actual body weight). Serum creatinine 2.4 mg/dL; not on dialysis. After estimating creatinine clearance with Cockcroft-Gault (actual body weight), the daptomycin regimen should be:
- A560 mg every 24 hours
- B420 mg every 48 hours
- C280 mg every 24 hours
- D700 mg every 48 hours
- E560 mg every 48 hours
Show answer
Answer E
Source Cubicin (daptomycin) US prescribing information (FDA); IDSA 2011 Clinical Practice Guidelines for the Treatment of MRSA Infections
- DDI-020Multiple choiceClinical pharmacyIntermediate
A 66-year-old 60-kg woman with hospital-acquired pneumonia was to receive levofloxacin 750 mg daily. Serum creatinine 1.3 mg/dL and stable. After estimating creatinine clearance with Cockcroft-Gault (actual body weight), the correct levofloxacin regimen is:
- A750 mg every 24 hours, no adjustment
- B750 mg first dose, then 500 mg every 48 hours
- C750 mg first dose, then 750 mg every 48 hours
- D500 mg first dose, then 250 mg every 24 hours
- E250 mg every 48 hours
Show answer
Answer C
Source Levofloxacin injection US prescribing information (FDA)
- DDI-021Multiple choiceClinical pharmacyAdvanced
A 60-year-old man with end-stage renal disease on maintenance hemodialysis takes phenytoin for epilepsy. Serum albumin 3.0 g/dL; pre-dialysis total phenytoin level 6 µg/mL (reference 10-20 µg/mL); no recent seizures. After applying the adjustment equation appropriate for end-stage renal disease, the correct interpretation is:
- AAdjusted level about 15 µg/mL, within range; no dose increase now
- BAdjusted level about 8.6 µg/mL, below range; increase the dose
- CThe measured 6 µg/mL is below range; increase the dose
- DAdjusted level about 20 µg/mL, at the upper limit; reduce the dose
- EAdjusted level about 30 µg/mL, in the toxic range
Show answer
Answer A
Source Bauer LA, Applied Clinical Pharmacokinetics, 3rd ed. (phenytoin albumin adjustment in end-stage renal disease)
- DDI-022Multiple choiceClinical pharmacyAdvanced
A 60-year-old man is on vancomycin 1000 mg every 12 hours, each dose infused over 1 hour, at steady state. A level drawn 1 hour after the end of the infusion is 30 µg/mL and the trough before the next dose is 10 µg/mL. Using a one-compartment model with first-order elimination (linear trapezoid during the infusion, exponential decay afterward), AUC24 is closest to:
- AAbout 235 mg·h/L
- BAbout 470 mg·h/L
- CAbout 365 mg·h/L
- DAbout 430 mg·h/L
- EAbout 560 mg·h/L
Show answer
Answer B
Source 2020 ASHP/IDSA/PIDS/SIDP Consensus Guideline on Therapeutic Monitoring of Vancomycin for Serious MRSA Infections (two-level AUC method)
- DDI-023Short answerClinical pharmacyAdvanced
A 68-year-old woman with rheumatoid arthritis has taken methotrexate 15 mg once weekly for years. One week ago she self-started trimethoprim-sulfamethoxazole 160/800 mg twice daily for a urinary tract infection. She now has oral ulcers and T 101.5°F (38.6°C); WBC 1,100/µL (ANC 400/µL), Hb 8.2 g/dL, platelets 35,000/µL, serum creatinine 1.5 mg/dL (baseline 0.9). Explain the mechanism and give the key management steps.
Rubric
- +2Explains the mechanism: additive antifolate effect of trimethoprim and/or reduced renal excretion of methotrexate from sulfamethoxazole
- +2Stops methotrexate and TMP-SMX immediately
- +3Gives leucovorin rescue
- +2Febrile neutropenia: blood cultures then empiric IV antipseudomonal beta-lactam such as cefepime or meropenem (G-CSF is adjunctive only)
- +1Hydration/renal protection and avoiding NSAIDs or other drugs that worsen accumulation
- -3Uses folic acid instead of leucovorin
- -2Continues weekly methotrexate or only reduces the dose
- -2Withholds or delays empiric antibiotics for febrile neutropenia (e.g., relies on G-CSF alone)
Show answer
Reference answer Mechanism: trimethoprim inhibits dihydrofolate reductase, adding to methotrexate's antifolate effect; sulfamethoxazole competes with methotrexate for renal tubular secretion and displaces it from protein binding. Together with the decline in renal function, methotrexate accumulates, causing myelosuppression and mucositis. Management: (1) stop methotrexate and TMP-SMX immediately; (2) give leucovorin early (for example 15 mg every 6 hours, IV preferred with severe mucositis), adjusted to counts/methotrexate level until recovery - folic acid is not a substitute; (3) treat as febrile neutropenia: blood cultures then an IV antipseudomonal beta-lactam such as cefepime or meropenem (piperacillin-tazobactam can further reduce methotrexate clearance); consider G-CSF; transfuse platelets/red cells as needed; (4) hydrate, restore renal function and avoid drugs that further reduce methotrexate clearance (NSAIDs, PPIs); (5) monitor CBC, liver and renal function and methotrexate level.
Source Methotrexate tablets US prescribing information (FDA); Bactrim (sulfamethoxazole-trimethoprim) US prescribing information (FDA); IDSA 2010 Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer; 2018 ASCO/IDSA Outpatient Management of Fever and Neutropenia Guideline (extrapolated to drug-induced neutropenia)
- DDI-024Short answerClinical pharmacyIntermediate
A 76-year-old man with hypertension and heart failure takes ramipril 10 mg daily and furosemide 40 mg daily. He took ibuprofen 400 mg three times daily for 10 days for knee pain and has had gastroenteritis with vomiting, diarrhea and poor intake for 2 days. Today serum creatinine is 2.6 mg/dL (1.0 mg/dL 2 months ago), potassium 5.9 mEq/L, ECG shows peaked T waves, BP 98/58 mmHg. Identify the main problem and give the medication management.
Rubric
- +2Recognizes the ACE inhibitor + diuretic + NSAID 'triple whammy' with volume depletion
- +2Stops ibuprofen
- +2Holds ramipril and furosemide
- +2Gives IV calcium, shifts potassium and removes it (binder such as sodium zirconium cyclosilicate or patiromer; dialysis if refractory)
- +1IV fluids for hypovolemia
- +1Plans a staged ACE inhibitor restart and switches to acetaminophen or topical analgesia
- -3Increases furosemide to 'excrete potassium' without assessing volume
- -2Continues ramipril unchanged
Show answer
Reference answer This is the 'triple whammy' (ACE inhibitor + diuretic + NSAID) plus volume depletion causing AKI and hyperkalemia. (1) Stop ibuprofen; hold ramipril and furosemide (sick-day rules). (2) Assess volume and give cautious IV fluid boluses for hypovolemia, reassessing often given his heart failure. (3) Hyperkalemia with ECG changes: IV calcium gluconate to stabilize the myocardium; insulin plus dextrose and optionally nebulized albuterol to shift potassium; a potassium binder (sodium zirconium cyclosilicate or patiromer) to remove it; dialysis if needed; stop other potassium-raising drugs. (4) Monitor creatinine, electrolytes and urine output. (5) After recovery, reassess and restart the ACE inhibitor and diuretic stepwise; treat knee pain with acetaminophen or a topical NSAID and avoid systemic NSAIDs.
Source KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury; KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
- DDI-025Short answerClinical pharmacyIntermediate
A 45-year-old woman with bipolar disorder takes lithium carbonate 900 mg/day with levels consistently 0.7 mEq/L. Two weeks ago hydrochlorothiazide 25 mg daily was added for hypertension, and for 1 week she has been taking ibuprofen for back pain. She now has coarse tremor, ataxia and somnolence (GCS 12). Serum lithium 2.4 mEq/L (12 hours after the last dose), serum creatinine 1.8 mg/dL (baseline 0.8). Give the key management steps.
Rubric
- +2Recognizes thiazide and NSAID causing lithium accumulation
- +2Stops lithium and the precipitating drugs
- +2IV isotonic saline
- +3States hemodialysis is indicated now because of decreased level of consciousness, without waiting for a saline trial or a higher lithium level
- +1Rechecks lithium after dialysis and watches for rebound
- -2Gives activated charcoal
- -2Continues lithium at a reduced dose
Show answer
Reference answer Chronic lithium toxicity precipitated by a thiazide and an NSAID reducing renal lithium excretion, plus declining renal function. (1) Stop lithium, hydrochlorothiazide and ibuprofen. (2) IV isotonic saline to restore volume and promote lithium excretion; monitor sodium and urine output (watch for nephrogenic diabetes insipidus). (3) With decreased level of consciousness, hemodialysis is recommended per EXTRIP (decreased consciousness, seizures or life-threatening dysrhythmias warrant dialysis regardless of lithium level); dialyze until lithium is <1.0 mEq/L or there is clear clinical improvement, and monitor for at least 12 hours afterward for rebound. (4) Activated charcoal does not bind lithium - do not use it. (5) Cardiac monitoring; follow lithium, electrolytes and renal function. (6) After recovery, reassess the lithium dose; switch the antihypertensive to one that does not impair lithium excretion (for example a dihydropyridine calcium channel blocker such as amlodipine; avoid thiazides and ACE inhibitors/ARBs), avoid NSAIDs and monitor levels.
Source EXTRIP Workgroup 2015 Recommendations for Extracorporeal Treatment in Lithium Poisoning (Clin J Am Soc Nephrol); Lithium carbonate US prescribing information (FDA)
- DDI-026Short answerClinical pharmacyIntermediate
A 72-year-old woman takes citalopram 40 mg daily. She is admitted with community-acquired pneumonia and started on levofloxacin 750 mg daily, with IV ondansetron for nausea. On hospital day 2 the ECG shows QTc 520 ms (460 ms on admission); potassium 3.1 mEq/L, magnesium 1.5 mg/dL; no syncope. Give the key management steps.
Rubric
- +2Identifies the additive QT effect of citalopram, levofloxacin and ondansetron
- +2Stops or replaces the QT-prolonging drugs and gives a reasonable alternative antibiotic regimen
- +2Repletes potassium to ≥4.0 mEq/L and repletes magnesium
- +2Continuous ECG monitoring
- +1States the citalopram maximum is 20 mg/day over age 60
- +1Describes torsade management (IV magnesium sulfate)
- -3Switches to azithromycin as a 'QT-safe' alternative
- -2Adds amiodarone to prevent arrhythmias
Show answer
Reference answer Stacked QT-prolonging drugs (citalopram, levofloxacin, ondansetron) plus hypokalemia, hypomagnesemia, older age and female sex give a high torsade de pointes risk. (1) Continuous ECG monitoring. (2) Stop or replace QT-prolonging drugs: switch levofloxacin to a regimen without meaningful QT effect such as ceftriaxone plus doxycycline (macrolides also prolong QT); stop ondansetron; hold citalopram (the label advises discontinuing it if QTc stays >500 ms), then restart at ≤20 mg/day - the maximum over age 60 - or switch to an antidepressant with lower QT risk once QTc normalizes. (3) Replete potassium to ≥4.0 mEq/L and magnesium to normal (for example IV magnesium sulfate). (4) Repeat the ECG. (5) If torsade occurs: IV magnesium sulfate 2 g, raise potassium to 4.5-5.0 mEq/L, unsynchronized defibrillation if sustained or pulseless, and increase heart rate if needed (temporary pacing or isoproterenol).
Source AHA/ACCF 2010 Scientific Statement on Prevention of Torsade de Pointes in Hospital Settings; FDA Drug Safety Communications on citalopram and QT prolongation, 2011/2012; 2019 ATS/IDSA Guideline for Diagnosis and Treatment of Adults with Community-acquired Pneumonia
- DDI-027Short answerClinical pharmacyAdvanced
An 80-year-old 48-kg woman with atrial fibrillation and heart failure has taken digoxin 0.25 mg daily for years; amiodarone was added 2 weeks ago. She now has nausea, vomiting and yellow vision. ECG shows atrial fibrillation with a ventricular rate of 38/min and frequent PVCs in bigeminy. Serum creatinine 1.6 mg/dL, potassium 5.8 mEq/L, digoxin level 3.4 ng/mL (drawn >6 hours after the dose). Explain the cause and give management, including the calculation of the digoxin immune fab dose.
Rubric
- +2States amiodarone inhibits P-gp and raises digoxin levels, plus reduced renal function and low weight
- +2Stops digoxin
- +2Indicates digoxin immune fab (life-threatening bradyarrhythmia, ventricular arrhythmia, potassium >5 mEq/L)
- +1Correctly calculates about 2 vials
- +1States serum digoxin levels after fab cannot be used to judge response
- +2Restarts (if at all) at a renally adjusted low dose (e.g., ≤0.0625 mg daily or every other day) with level monitoring
- -3Continues digoxin, or uses electrical cardioversion for the bradycardia/PVCs
- -2Uses IV calcium instead of fab or delays fab because of it
Show answer
Reference answer Cause: amiodarone inhibits P-gp and reduces digoxin clearance, raising levels by roughly 70-100%; older age, low weight and reduced renal function (Cockcroft-Gault CrCl about 21 mL/min) add to accumulation; 0.25 mg daily is clearly too much for her. Management: (1) stop digoxin and reassess the need for amiodarone; (2) with severe bradycardia, ventricular arrhythmia and hyperkalemia, give digoxin immune fab: for chronic toxicity, vials ≈ serum digoxin (ng/mL) × weight (kg) / 100 = 3.4 × 48 / 100 ≈ 1.6, rounded up to 2 vials; (3) hyperkalemia is corrected mainly by the fab (insulin plus dextrose can be used); atropine for bradycardia and temporary pacing if needed; avoid cardioversion unless VF/pulseless VT; (4) after fab, total serum digoxin no longer reflects free drug and cannot guide therapy; (5) watch for hypokalemia after fab and for free-digoxin rebound in renal impairment; (6) if digoxin is restarted, use a much lower dose (for example 0.0625 mg daily or every other day, targeting a level of about 0.5-0.9 ng/mL; the label advises reducing digoxin by 30-50% or extending the interval when amiodarone is started) and monitor levels.
Source Lanoxin (digoxin) US prescribing information (FDA); Amiodarone tablets US prescribing information (FDA); DigiFab (digoxin immune fab) US prescribing information (FDA)
- DDI-028Short answerClinical pharmacyAdvanced
A 42-year-old man 2 years after kidney transplantation takes tacrolimus 3 mg every 12 hours (troughs 6-8 ng/mL), mycophenolate mofetil 750 mg every 12 hours and prednisone 5 mg daily. He now has drug-susceptible pulmonary tuberculosis. Give the key points for managing the rifamycin component of TB therapy together with his immunosuppressants.
Rubric
- +2States rifampin induces CYP3A4/P-gp and markedly lowers tacrolimus levels
- +3Prefers rifabutin over rifampin
- +2Monitors tacrolimus troughs closely and adjusts the dose (a large increase with rifampin, smaller adjustments with rifabutin)
- +2Tapers tacrolimus, guided by troughs, after the rifamycin is stopped
- +1Mentions increasing prednisone or reduced mycophenolic acid exposure
- -3Stops tacrolimus during TB therapy
- -2Keeps the tacrolimus dose unchanged with only routine monthly monitoring
Show answer
Reference answer Rifampin is a potent CYP3A4 and P-gp inducer: it lowers tacrolimus levels markedly (often requiring several-fold dose increases), speeds prednisone metabolism and reduces mycophenolic acid exposure, so rejection risk is high. (1) Prefer rifabutin over rifampin (weaker induction, smaller tacrolimus adjustments, still needs monitoring). (2) If rifampin must be used: increase tacrolimus substantially (often 3-5 times the original dose) and check troughs once or twice weekly until stable; roughly double prednisone. (3) Induction peaks about 1-2 weeks after starting and wears off about 2 weeks after stopping the rifamycin; taper tacrolimus stepwise, guided by troughs, over about 2 weeks after the rifamycin stops to avoid nephrotoxicity. (4) Monitor graft function and liver tests (isoniazid, rifamycin and pyrazinamide hepatotoxicity). (5) Co-manage with transplant, infectious diseases and clinical pharmacy. The '3-5 times' figure is empirical; troughs guide dosing.
Source ATS/CDC/IDSA 2016 Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis; AST Infectious Diseases Community of Practice 2019 Guideline on Tuberculosis in Solid Organ Transplant Recipients; Prograf (tacrolimus) US prescribing information (FDA)
- DDI-029Short answerClinical pharmacyIntermediate
A 72-year-old 70-kg man is on day 2 of COVID-19 symptoms, does not need oxygen and has high-risk factors; nirmatrelvir/ritonavir is planned. Current medications: simvastatin 20 mg nightly, amlodipine 5 mg daily, metformin 500 mg twice daily. eGFR 45 mL/min/1.73 m², normal liver function. Give the nirmatrelvir/ritonavir dose and how to manage his other medications.
Rubric
- +3Reduces the dose for eGFR 30-60 to nirmatrelvir 150 mg + ritonavir 100 mg twice daily
- +2Holds simvastatin during treatment (pravastatin may be used in the interim)
- +1Stops simvastatin ≥12 hours before the first dose and resumes it 5 days after the last dose
- +2Monitors blood pressure/edema on amlodipine and reduces it if needed
- +1States metformin needs no adjustment
- -3Uses full-dose nirmatrelvir 300 mg
- -3Continues simvastatin during treatment
- -2States the drug is contraindicated at eGFR 45
Show answer
Reference answer (1) eGFR ≥30 to <60 requires dose reduction: nirmatrelvir 150 mg + ritonavir 100 mg twice daily for 5 days (started within 5 days of symptom onset). (2) Simvastatin is a sensitive CYP3A4 substrate and is contraindicated with ritonavir: stop it at least 12 hours before starting, keep it off during treatment and for 5 days after, then resume (pravastatin can be used in the interim if needed). (3) Amlodipine levels rise: monitor blood pressure, dizziness and edema, and reduce the dose if needed. (4) Metformin has no meaningful interaction and needs no change. (5) Review the full medication list, including OTC and herbal products, before starting.
Source Paxlovid (nirmatrelvir tablets; ritonavir tablets) US prescribing information (FDA), current version
- DDI-030Short answerClinical pharmacyIntermediate
A 70-year-old woman with atrial fibrillation takes warfarin 3 mg daily with an INR stable at 2.0-3.0. For vaginal candidiasis she took fluconazole 150 mg, then 3 days later took it again for 3 more consecutive days on her own; the last dose was 2 days ago. Today's routine INR is 9.2 with no bleeding, stable hemoglobin, and no planned procedures. Give management and follow-up advice.
Rubric
- +2Identifies fluconazole inhibition of CYP2C9 as the cause of the INR rise
- +2Holds warfarin and rechecks INR within 24-48 hours
- +2No routine vitamin K without bleeding (or only low-dose oral)
- +2Restarts after INR falls (reduced or usual dose) with closer monitoring
- +1States IV phytonadione plus 4F-PCC for major bleeding
- +1Counsels her to check before using azoles or other interacting drugs
- -3Gives FFP or PCC despite no bleeding
- -2Gives IV vitamin K, or more than 5 mg orally, without bleeding
Show answer
Reference answer Fluconazole inhibits CYP2C9 (the main enzyme for S-warfarin), causing a marked INR rise. (1) Hold warfarin and recheck INR within 24-48 hours. (2) For INR 4.5-10 without bleeding, ACCP 2012 suggests against routine vitamin K; patients at high bleeding risk may receive low-dose oral phytonadione (vitamin K1) 1-2.5 mg. (3) Prothrombin complex concentrate or fresh frozen plasma is not needed. (4) Restart at a reduced (or the usual) dose once INR is back in range, with closer monitoring; fluconazole's long half-life means the effect persists for days after the last dose. (5) Counsel her to tell her clinician or pharmacist before using azole antifungals (vaginal or oral), TMP-SMX or metronidazole. (6) Once fluconazole has cleared (about 1-2 weeks), return gradually to the usual warfarin dose. (7) If major bleeding occurs: stop warfarin, give IV phytonadione 5-10 mg plus four-factor PCC.
Source ACCP 2012 Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. (Holbrook et al.); 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants; Warfarin sodium tablets US prescribing information (FDA); Diflucan (fluconazole) US prescribing information (FDA)